Last update 11 Dec 2024
Alemtuzumab biosimilar (Shanghai Zhangjiang Biotech)
Last update 11 Dec 2024
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms- |
Target |
Mechanism CD52 inhibitors(CAMPATH-1 antigen inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Complement dependent cytotoxicity (CDC) effects |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseSuspendedPhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 53002L
The sequence is quoted from: *****
Sequence Code 53009H
The sequence is quoted from: *****
Related
3
Clinical Trials associated with Alemtuzumab biosimilar (Shanghai Zhangjiang Biotech)重组抗CD52人源化单抗注射液单药治疗复发难治的慢性淋巴细胞性白血病的多中心、开放性、前瞻性II期临床研究
[Translation] A multicenter, open, prospective phase II clinical study of recombinant anti-CD52 humanized monoclonal antibody injection in the treatment of relapsed and refractory chronic lymphocytic leukemia
A Multi-center, Open, Prospective, Phase II Study of Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection in Patients With Relapse and Refractory B-cell Chronic Lymphocytic Leukemia
重组抗CD52人源化单克隆抗体治疗淋巴细胞性白血病的Ⅰ期临床研究
[Translation] Phase I clinical study of recombinant anti-CD52 humanized monoclonal antibody in the treatment of lymphocytic leukemia
100 Clinical Results associated with Alemtuzumab biosimilar (Shanghai Zhangjiang Biotech)
Login to view more data
100 Translational Medicine associated with Alemtuzumab biosimilar (Shanghai Zhangjiang Biotech)
Login to view more data
100 Patents (Medical) associated with Alemtuzumab biosimilar (Shanghai Zhangjiang Biotech)
Login to view more data
100 Deals associated with Alemtuzumab biosimilar (Shanghai Zhangjiang Biotech)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic lymphocytic leukaemia refractory | Phase 2 | CN | 01 Jul 2011 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free